Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fisher

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2015
Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of SurvivalChristopher G Smith, David Fisher, Rebecca Harris, et al.
Nature Communications|April 17, 2023
Chromosome-level genome assembly and population genomic resource to accelerate orphan crop lablab breedingIsaac Njaci, Bernice Waweru, Nadia Kamal, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
Annals of Surgery|April 29, 2021
Bariatric Surgery and Risk of Death in Persons With Chronic Kidney DiseaseKaren J Coleman, Yu-Hsiang Shu, Heidi Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2014
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studiesSabine Venderbosch, Iris D Nagtegaal, Tim S Maughan, et al.
The Lancet. Oncology|June 7, 2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialRichard A Adams, Angela M Meade, Matthew T Seymour, et al.
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trialsClaire Vale, Peter J Godolphin, David Fisher, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2015
Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of SurvivalChristopher G Smith, David Fisher, Rebecca Harris, et al.
Nature Communications|April 17, 2023
Chromosome-level genome assembly and population genomic resource to accelerate orphan crop lablab breedingIsaac Njaci, Bernice Waweru, Nadia Kamal, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
Annals of Surgery|April 29, 2021
Bariatric Surgery and Risk of Death in Persons With Chronic Kidney DiseaseKaren J Coleman, Yu-Hsiang Shu, Heidi Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2014
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studiesSabine Venderbosch, Iris D Nagtegaal, Tim S Maughan, et al.
The Lancet. Oncology|June 7, 2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialRichard A Adams, Angela M Meade, Matthew T Seymour, et al.
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trialsClaire Vale, Peter J Godolphin, David Fisher, et al.
Pageof 19